Kura Oncology (KURA) News Today $10.80 +0.74 (+7.36%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period HC Wainwright Issues Positive Forecast for Kura Oncology (NASDAQ:KURA) Stock PriceNovember 23 at 4:15 AM | americanbankingnews.comKura Oncology (NASDAQ:KURA) Shares Gap Down Following Analyst DowngradeNovember 23 at 2:37 AM | americanbankingnews.comKura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%November 22 at 12:34 PM | msn.comKura Oncology’s Strategic Developments and Partnership with Kyowa Kirin Justify Buy Rating, Despite Initial Stock DipNovember 22 at 11:57 AM | markets.businessinsider.comBofA lowers Kura Oncology price target to $29, sees buying opportunityNovember 22 at 11:57 AM | markets.businessinsider.comKura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst UpgradeKura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume After Analyst UpgradeNovember 22 at 10:55 AM | marketbeat.comBank of America Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock PriceBank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Friday.November 22 at 8:18 AM | marketbeat.comKura selling off on loss of acquisition premium, says TD CowenNovember 22 at 7:36 AM | markets.businessinsider.comKura Oncology (KURA) Gets a Hold from Stifel NicolausNovember 22 at 1:48 AM | markets.businessinsider.comKura Oncology (KURA) Gets a Hold from Stifel NicolausNovember 22 at 1:48 AM | markets.businessinsider.comKura Oncology price target lowered to $34 from $37 at WedbushNovember 22 at 1:48 AM | markets.businessinsider.comKura Oncology price target lowered to $34 from $37 at WedbushNovember 22 at 1:48 AM | markets.businessinsider.comKura Oncology: A Contender In The Field Of Precision MedicineNovember 22 at 1:48 AM | seekingalpha.comKura Crashes 37% After $1.53 Billion Deal Slams The Door On A TakeoverNovember 22 at 1:48 AM | msn.comKura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely BullishNovember 21 at 4:29 PM | msn.comKura Crashes 35% After $1.53 Billion Deal Slams The Door On A TakeoverNovember 21 at 4:29 PM | msn.comKura Oncology (NASDAQ:KURA) Price Target Raised to $37.00HC Wainwright increased their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday.November 21 at 8:11 AM | marketbeat.comKura Oncology partners Kyowa Kirin to advance AML treatmentNovember 21 at 6:58 AM | yahoo.comJMP Securities Reaffirms "Market Outperform" Rating for Kura Oncology (NASDAQ:KURA)November 21 at 4:39 AM | americanbankingnews.comKura stock slides 17% on Kyowa Kirin deal for ziftomenibNovember 20 at 9:02 PM | msn.comKura Oncology to partner with Kyowa Kirin for blood cancer therapyNovember 20 at 5:52 PM | reuters.comKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNovember 20 at 5:00 PM | globenewswire.comKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNovember 20 at 5:00 PM | prnewswire.comStockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to SellStockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday.November 20 at 3:23 AM | marketbeat.comKura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday.November 19, 2024 | marketbeat.comKura Oncology: A Compelling Buy Amidst Growth Potential and Strategic AdvancementsNovember 19, 2024 | markets.businessinsider.comPromising Developments and Strategic Advantages Elevate Kura Oncology’s ProspectsNovember 18, 2024 | markets.businessinsider.comPositive Outlook on Kura Oncology’s Growth Potential Amid Competitive LandscapeNovember 17, 2024 | markets.businessinsider.comKura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor ChallengesNovember 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Kura Oncology: Ziftomenib’s Competitive Edge and Strong Safety ProfileNovember 14, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA)HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Wednesday.November 13, 2024 | marketbeat.comLeerink views Syndax data as potentially positive for Kura Oncology’s ziftomenibNovember 13, 2024 | markets.businessinsider.comStrong Buy Rating for Kura Oncology Based on Promising Menin Inhibitor TrialsNovember 13, 2024 | markets.businessinsider.comKura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comKura Oncology’s Promising Catalysts and Clinical Progress Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comFY2026 EPS Estimates for Kura Oncology Boosted by AnalystKura Oncology, Inc. (NASDAQ:KURA - Free Report) - Brookline Capital Management upped their FY2026 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, November 7th. Brookline Capital Management analyst L. Cann now anticipNovember 11, 2024 | marketbeat.comKura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by AnalystsKura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has earned a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buyNovember 10, 2024 | marketbeat.comKura Oncology, Inc. (KURA) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comKura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ExpensesNovember 8, 2024 | uk.finance.yahoo.comKura Oncology Positioned for Growth with Promising Trial Developments and Strong FinancialsNovember 8, 2024 | markets.businessinsider.comKura Oncology (NASDAQ:KURA) Shares Gap Down - Here's WhyKura Oncology (NASDAQ:KURA) Shares Gap Down - What's Next?November 8, 2024 | marketbeat.comKura Oncology Receives Buy Rating: Promising Developments in NPM1m AML Treatment and Attractive ValuationNovember 8, 2024 | markets.businessinsider.comKura Oncology (KURA) Receives a Buy from BarclaysNovember 8, 2024 | markets.businessinsider.comPhil Nadeau Affirms Buy Rating on Kura Oncology Thanks to Promising Clinical Trials and Robust Financial PositionNovember 8, 2024 | markets.businessinsider.comKura Oncology Receives ‘Buy’ Rating: Promising Ziftomenib Data and Strategic Positioning HighlightedNovember 7, 2024 | markets.businessinsider.comKura Oncology Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPromising Outlook for Kura Oncology: Positive Phase 1 KOMET-007 Trial Results Support Buy RatingNovember 6, 2024 | markets.businessinsider.comKura Oncology's (KURA) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a research note on Wednesday.November 6, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Kura Oncology (NASDAQ:KURA)HC Wainwright reissued a "buy" rating and set a $32.00 target price on shares of Kura Oncology in a research note on Wednesday.November 6, 2024 | marketbeat.comKura Oncology to present updated data from KOMET-007 trialNovember 5, 2024 | markets.businessinsider.com Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> KURA Media Mentions By Week KURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KURA News Sentiment▼0.130.49▲Average Medical News Sentiment KURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KURA Articles This Week▼335▲KURA Articles Average Week Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZYME News IRWD News IGMS News ZNTL News PRLD News HCM News MRUS News VRNA News XENE News DYN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KURA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
